Epileptic seizures are by far the most concerning problems that many patients with certain genetic syndromes like Rett, Angelman syndrome, fragile x syndrome, Lennox-gastaut syndrome, etc experience. Epilepsy in these cases is often refractory meaning no matter what combination of meds, dosing, etc is given, these patients still have breakthrough seizures.
All it will take is a Rett trial that can show a clinically significant reduction in seizure frequency relative to baseline compared to a placebo control group. A secondary endpoint of 50% responder rate as well as other secondary endpoints can be included.
This is a study that can be done quickly.
IF the Rett trial shows decline in seizures, my oh my will the floodgates open. Then every epileptologist in the country (me included) will demand that it be tried on our refractory epileptic patients, that it be included for treatment of Lennox gastaut syndrome and other epileptic encephalopathies. I will even be willing to try on infantile spasms. Epilepsy indication can then jump way up to advanced phase 3 trials as adjunctive treatment and monotherapy treatment for focal epilepsy and possibly even generalized epilepsy.
I will be attending AES (American Epilepsy Society) this year in DC and hope to see something g Rett related this December. I expect Q4 of 2017 to be positively transformational for Anavex Life Sciences.
As always, my opinion only. Do your own due diligence.
Market Data 
Markets 
AI
